comprehensive -WSS

comprehensive

author：fashion 2025-10-01 21:37:19 - browse：527

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： What a koala virus tells us about the human genome

knowledge

focus

WSS

The simple reason for the increase in autism diagnosis

Lilly’s weekly insulin works as well as daily products, new studies show

CVS is willing to dump 10% of its Medicare Advantage members

Ripples from Flovent's discontinuation is killing children with asthma

Here's how to stay safe from wildfire smoke amid reduced air quality

Obesity drug from Roche shows promise in early study

hotspot

comprehensive

entertainment

New air purifier tech could be key to improving indoor air quality

Ripples from Flovent's discontinuation is killing children with asthma

Jerome Adams on the need for new antivirals for Covid

ALS treatment from Biogen, Ionis fails in study

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

At least 13 dead in Texas as scorching temps continue

Brazil's Jair Bolsonaro is barred from running for office until 2030

Medical leaders decry Supreme Court decision on affirmative action

Cherokee Nation medical school graduates its first class

focus

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Obesity drug from Roche shows promise in early study

Supreme Court rules employers must be more accommodating of religious observance

Fertility clinic egg and embryo storage is a disaster

Supreme Court strikes down Biden student loan forgiveness program

STAT series 'Denied by AI' wins major journalism prizes

knowledge

hotspot

focus

hotspot